For research use only. Not for therapeutic Use.
Lacidipine is a L-type calcium channel blocker, used for treating high blood pressure.<br>Lacidipine, an L-type Ca(2+) channel blocker that also inhibits [Ca(2+)](ER) efflux, enhances folding, trafficking, and activity of degradation-prone glucocerebrosidase (GC) variants. Lacidipine remodels mutated GC proteostasis by simultaneously activating a series of distinct molecular mechanisms, namely modulation of Ca(2+) homeostasis, upregulation of the ER chaperone BiP, and moderate induction of the unfolded protein response.<br>Lacidipine has non-significant effects on blood pressure but inhibits the paradoxical increases in plasma renin activity (PRA) and in renin mRNA in kidney that are found in salt-loaded stroke-prone spontaneously hypertensive rats (SHRSP). Lacidipine restores the physiological downregulation of renin production by high salt and reduces left ventricular hypertrophy and mRNA levels of atrial natriuretic factor and transforming growth factor-beta1.
| Catalog Number | A000957 |
| CAS Number | 103890-78-4 |
| Synonyms | GX-1048,GR-43659X,SN-305 |
| Molecular Formula | C26H33NO6 |
| Purity | ≥95% |
| Target | Calcium Channel |
| Solubility | >21.3mg/mL in DMSO |
| Storage | 3 years -20C powder |
